The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Immunocore (Inst); Pfizer (Inst)
 
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; MSD; Pierre Fabre
Consulting or Advisory Role - Delcath Systems; Immunocore; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); MSD (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Immunocore; Incyte; Ipsen; Merck; MSD; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - Immunocore (Inst); Novartis (Inst)
 
Consulting or Advisory Role - Castle Biosciences; Genzyme; Immunocore; InxMed; Iovance Biotherapeutics; Merck; OncoSec; Pierre Fabre; PureTech; Regeneron; Sorrento Therapeutics; TriSalus Life Sciences
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Bristol Myers Squibb Foundation; MSD; Novartis; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst)
 
Piotr Rutkowski
No Relationships to Disclose
 
Jean-Francois Baurain
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Sanofi/Regeneron (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; Iovance Biotherapeutics; LaRoche Posay; Merck; Novartis; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Max Schlaak
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme; Immunocore; Kyowa Kirin; MSD; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Novartis; Pierre Fabre; Sun Pharma
 
Ryan Sullivan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Amgen (Inst); Merck (Inst)
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; Ipsen; Merck Serono; MSD
Consulting or Advisory Role - Bayer; BMS; Janssen-Cilag; Merck Serono; MSD
Research Funding - BMS
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Merck Serono
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Elsevier; Harbour BioMed; Iovance Biotherapeutics; Istari Oncology; Novartis; OncoSec; Pfizer; Scopus BioPharma
Speakers' Bureau - BMS
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Anthony M. Joshua
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Joseph J. Sacco
No Relationships to Disclose
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - Bristol-Myers Squibb; Immunocore; Polaris; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Marlana Orloff
Consulting or Advisory Role - Immunocore
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Richard D. Carvajal
No Relationships to Disclose
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Shaad Essa Abdullah
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
Patents, Royalties, Other Intellectual Property - AU2019270277A1 - Treatment of Cancer; WO2020225552A1 - Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
 
Chris Holland
Employment - Immunocore
Stock and Other Ownership Interests - Amgen; Immunocore; MacroGenics
Patents, Royalties, Other Intellectual Property - Co-involvement in a patent for the compositions and methods for treating diffuse large B cell lymphoma
 
Howard Goodall
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Paul Nathan
No Relationships to Disclose
 
Sophie Piperno-Neumann
Consulting or Advisory Role - Immunocore
Research Funding - MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis; PharmaMar